DermTech, Inc. (DMTK) Financial Analysis & Valuation | Quarter Chart
DermTech, Inc. (DMTK)
DMTKPrice: $0.09
Fair Value: 🔒
🔒score
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of g... more
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tes... more
Description
Shares
| Market Cap | $3.29M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Bret Christensen |
| IPO Date | 2017-08-10 | CAGR | — |
| Employees | 206 | Website | www.dermtech.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
DMTK chart loading...
Fundamentals
Technicals
| Enterprise Value | $50.06M | P/E Ratio | -0.04 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-2.65 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 9.71% | Gross Margin | 0.02% |
| Operating Margin | -6.78% | Profit Margin | -6.6% |
| ROE | -1.06% | ROA | -0.83% |
| ROCE | -0.96% | Current Ratio | 4.59 |
| Quick Ratio | 4.52 | Cash Ratio | 2.73 |
| Debt/Equity | 0.95 | Interest Coverage | -20747.8 |
| Altman Z Score | -8.39 | Piotroski Score | 4 |